XNAS
KURA
Market cap933mUSD
Oct 08, Last price
10.52USD
1D
-1.41%
1Q
-8.12%
Jan 2017
78.31%
IPO
30.36%
Name
Kura Oncology Inc
Chart & performance
P/E
—
P/S
13.84
EPS
—
Div yield, %
—
Shrs. gr., 5y
10.56%
Rev. gr., 5y
%
Revenues
67m
+25.24%
Net income
-279m
L+60.17%
CFO
-64m
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Key people
Chairman of the Board, President, Chief Executive Officer · since 2018
Marc Grasso
Chief Financial Officer and Chief Business Officer · since 2019
John Farnam
Chief Operating Officer · since 2018
Liu Yi
Chief Scientific Officer · since 2015
Acting Chief Medical Officer · since 2020
Director · since 2018
Independent Director · since 2015
Independent Director · since 2019
Independent Director · since 2017
Legal address
c/o NATIONAL REGISTERED AGENTS, INC., 1209 ORANGE STREET
WILMINGTON, DE 19801
US
WILMINGTON, DE 19801
US
Headquarters
11119 North Torrey Pines Road
La Jolla, CA 92037
US
La Jolla, CA 92037
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||